Pharmacotherapeutic strategies for the management of erectile dysfunction in patients with diabetes and pre-diabetes.

Oral phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line therapy for erectile dysfunction even in patients with diabetes mellitus.

• PDE5i are recommended as first-line treatment regardless of diabetic status.
• This recommendation applies to patients with both pre-diabetes and diabetes mellitus.
• PDE5i may be used alone or in combination with testosterone replacement therapy.

Testosterone replacement therapy (TRT) is mandatory in all hypogonadal subjects with erectile dysfunction.

• Hypogonadism is defined by a total testosterone threshold of less than 12 nmol/l.
• TRT is indicated in combination with PDE5i in hypogonadal patients with ED.
• TRT is described as 'mandatory' rather than optional for qualifying patients.

Alprostadil and/or combined therapeutic approaches can be considered when PDE5i with or without TRT fail.

• Alprostadil is positioned as a second-line or salvage therapy option.
• Combined approaches are included as alternatives when first-line treatments are insufficient.
• This step applies whether TRT has or has not been added to PDE5i therapy.

Glycometabolic optimization through lifestyle modification and hypoglycemic drugs represents a crucial step for erectile dysfunction treatment in diabetic patients.

• Lifestyle modification is identified as a key component of ED management in this population.
• Hypoglycemic drug selection is considered relevant not just for glycemic control but also for ED outcomes.
• The paper emphasizes the strong association between ED and forthcoming cardiovascular diseases in this context.

GLP-1 receptor analogues or SGLT-2 inhibitors represent the best pharmacological option for hypoglycemic therapy in diabetic patients with erectile dysfunction.

• Selection of these agents is favored due to their long-term effect on chronic complication prevention.
• The strong association between ED and forthcoming cardiovascular diseases informs this recommendation.
• These drug classes are preferred over other hypoglycemic agents in more complicated patients.

Metformin can be considered a possible alternative hypoglycemic agent in less complicated subjects with erectile dysfunction.

• Metformin is positioned as an alternative rather than preferred agent.
• Its use is specifically noted for 'less complicated subjects,' implying it is not the first choice in high-risk patients.
• This contrasts with GLP-1 analogues and SGLT-2 inhibitors recommended for more complex cases.

Penile prostheses can be offered when all other treatment options are ineffective, but poor glycometabolic control increases the risk of prosthesis infection.

• Penile prostheses (PP) are positioned as a last-resort option after failure of medical therapies.
• Patients must be informed that poor glycometabolic control can increase the risk of PP infection.
• This finding underscores the importance of glycemic optimization even in patients proceeding to surgical intervention.

Erectile dysfunction is characterized as a neglected complication in patients with pre-diabetes or diabetes mellitus.

• The paper identifies ED as underrecognized and undertreated in the diabetic population.
• Both pre-diabetes and established diabetes mellitus are included in this characterization.
• The review aims to summarize standard ED treatment as well as the contribution of lifestyle modification and hypoglycemic drugs.